1. In a guinea-pig model of allergic
asthma, we investigated the involvement of the
tachykinin NK2 receptors in
allergen-induced early (EAR) and late (LAR) asthmatic reactions, airway hyperreactivity (AHR) after these reactions and inflammatory cell influx in the airways, using the selective non-
peptide NK2 receptor antagonist
SR48968. 2. On two different occasions, separated by a 1 week interval,
ovalbumin (OA)-sensitized guinea-pigs inhaled either vehicle (3 min) or
SR48968 (100 nM, 3 min) at 30 min before as well as at 5.5 h after OA provocation (between the EAR and LAR) in a random crossover design. 3.
SR48968 had no significant effect on the EAR, but significantly attenuated the LAR by 44.2+/-16.4% (P<0.05) compared to saline control. 4. The NK2 receptor antagonist did not affect the OA-induced AHR to
histamine after the EAR at 5 h after OA challenge (3.59+/-0.59 fold increase in
histamine reactivity vs 3.79+/-0.61 fold increase in the controls, NS), but significantly reduced the AHR after the LAR at 23 h after OA challenge (1.59+/-0.24 fold increase vs 1.93+/-0.15 fold increase, respectively, P<0.05). 5. Bronchoalveolar lavage studies performed at 25 h after the second OA provocation showed that
SR48968 significantly inhibited the
allergen-induced infiltration of neutrophils (P<0.05) and lymphocytes (P<0.01) in the airways. 6. These results indicate that NK2 receptor activation is importantly involved in the development of the
allergen-induced late (but not early) asthmatic reaction and late (but not early) AHR to
histamine, and that NK2 receptor-mediated infiltration of neutrophils and lymphocytes in the airways may contribute to these effects.